Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes

American Journal of Gastroenterology

Volumn 94, Issue 4, 1999, Pages 976-981

  Hiroyoshi, M ^a   Tateishi, K ^a   Yasunami, Y ^a   Maeshiro, K ^a   Ono, J ^a   Matsuoka, Y ^a   Ikeda, S ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; HUMAN; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

C-PEPTIDE; CASE-CONTROL STUDIES; CHRONIC DISEASE; DIABETES MELLITUS; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; PANCREATITIS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; TIME FACTORS;

EID: 0033119424     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00098-2     Document Type: Article

References (27)

1. Parley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-62.
2. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16:75-85.
3. Zunz E, La Barre J. Contributions a l'étude des variations physiologiques de la secretion interne du pancreas: Relation entre les secretions extrene et interne du pancreas. Arch Inter Physiol Biochim 1929;31:20.
4. Mojsov S, Heinrich G, Wilson IB, et al. Preproglucagon gène expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986;26I: 11880-9.
5. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2:1300-4.
6. Mojsov S, Weir GC, Habener JF. Insulinotropin: Glucagonlike peptide-1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-9.
7. Mclntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol 1965;25: 1317-24.
8. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985;28:565-73.
9. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-l(7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138:159-66.
10. Orskov C, Bersani M, Johnsen AH, et al. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 1989;264:12826-9.
11. Kreymann B, Yiangou Y, Kanse S, et al. Isolation and characterization of GLP-1 7-36 amide from rat intestine. Elevated levels in diabetic rats. FEBS Lett 1988;242:167-70.
12. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28:704-7.
13. Shima K, Hirota M, Ohboshi C. Effect of glucagon-like peptide-1 on insulin secretion. Regul Peptide 1988;22:245-52.
14. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)amide. Diabetes 1989;38:902-5.
15. D'Alessio DA, Kahn SE, Leusner CR, et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994;93:2263-6.
16. Orskov C, Jeppesen J, Madsbad S, et al. Proglucagon products in plasma of non insulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991;87:415-23.
17. Tateishi K, Shima K, Funakoshi A, et al. Glucagon-like peptide-l(GLP-l) molecular forms in human pancreatic endocrine tumors resemble those in intestine rather than pancreas. Diabetes Res Clin Pract 1994;25:43-9.
18. Kitayama N, Tateishi K, Funakoshi A, et al. Pancreastatin molecular forms in normal human plasma. Life Sei 1994;54: 1571-8.
19. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993;361:362-5.
20. Kruszynska YT, Ghatei MA, Bloom SR, et al. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis. Hepatology 1995;21:933-41.
21. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996;97:92-103.
22. Nauck MA, Bartels E, Orskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-l-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-7.
23. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagon like peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42:658-61.
24. Sugiyama K, Manaka H, Kalo T, et al. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 1994;55: 24-8.
25. Creutzfeldt WOG, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-6.
26. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53.
27. Rachman J, Barrow B A, Levy JC, et al. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40:205-11.